Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin vs Spiriva in COPD with Low PIFR
NCT03095456Phase 3Completed
- Sponsor
- Mylan
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Started Mar 2017; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03095456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095456.